Activin A activation of Smad3 mitigates innate inflammation in mouse models of psoriasis and sepsis
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci187063 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Thierry Gauthier und 11 weiteren Autor:innen. Beteiligte Einrichtung: Mucosal Immunology Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Activins, Smad3 Protein, Sepsis, Psoriasis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Intramural NIH HHS, National Institutes of Health.
Themen: Sepsis
Abstract (Originalsprache)
Phosphorylation of Smad3 is a critical mediator of TGF-β signaling, which plays an important role in regulating innate immune responses. However, whether Smad3 activation can be regulated in innate immune cells in TGF-β–independent contexts remains poorly understood. Here, we show that Smad3 is activated through the phosphorylation of its C-terminal residues (pSmad3C) in murine and human macrophages in response to bacterial and viral ligands, and this activation is mediated by activin A in a TGF-β–independent manner. Specifically, infectious ligands, such as LPS, induced secretion of activin A through the transcription factor STAT5 in macrophages, and activin A signaling in turn activated pSmad3C. This activin A/Smad3 axis controlled mitochondrial ATP production and ATP conversion into adenosine by CD73 in macrophages, enforcing an antiinflammatory mechanism. Consequently, mice with a deletion of activin A receptor 1b specifically in macrophages ( Acvr1b fl/fl - Lyz2cre) succumbed more to sepsis as a result of uncontrolled inflammation and exhibited exacerbated skin disease in a mouse model of imiquimod-induced psoriasis. Thus, we have revealed a previously unrecognized natural brake to inflammation in macrophages that occurs through the activation of Smad3 in an activin A–dependent manner.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mucosal Immunology Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, USA.
- Department of Pathology, Uniformed Services University, Bethesda, Maryland, USA.
- Genomics and Computational Biology Core, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland, USA.
- Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York, USA.
Förderung
- NIAID NIH HHS
- Intramural NIH HHS
- National Institutes of Health
Zitieren
APA
Gauthier, T., Lim, Y. J., Jin, W., Liu, N., Patiño, L. C., Chen, W., Warren, J., Martin, D., Morell, R. J., Dveksler, G., Su, G. H., & Chen, W. (2025). Activin A activation of Smad3 mitigates innate inflammation in mouse models of psoriasis and sepsis. Journal of Clinical Investigation. https://doi.org/10.1172/jci187063
Vancouver
Gauthier T, Lim YJ, Jin W, Liu N, Patiño LC, Chen W, et al. Activin A activation of Smad3 mitigates innate inflammation in mouse models of psoriasis and sepsis. Journal of Clinical Investigation. 2025. doi:10.1172/jci187063
BibTeX
@article{Gauthier2025,
author = {Gauthier, Thierry and Lim, Yun-Ji and Jin, Wenwen and Liu, Na and Patiño, Liliana C and Chen, Weiwei and Warren, James and Martin, Daniel and Morell, Robert J and Dveksler, Gabriela and Su, Gloria H and Chen, WanJun},
title = {Activin A activation of Smad3 mitigates innate inflammation in mouse models of psoriasis and sepsis},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci187063}
}
EUVIMED